Biologic viral safety is entering a new phase. Updated global ICH guidance is reshaping how manufacturers approach risk based controls, modern analytics and manufacturing innovation. In this PharmTech feature, John M. e...
ICON experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
Logistical considerations in mRNA vaccine development
In this article, ICON’s Andreas Dreps and Martin Lachs discuss the logistical considerations in mRNA vaccine development.
©BioPharm International
-
ICON partners with US Government for clinical trials of Covid-19 vaccines
The article on Clinical Trials Arena reports that ICON will conduct a phase 2b clinical trial for the US BARDA-selected Covid-19 vaccine candidate as part of Project NextGen.
-
BARDA, ICON partner to execute next-gen COVID vaccine trial
This news article from Contract Pharma reports that ICON will execute a Phase 2b clinical trial to assess the relative efficacy of a next generation COVID-19 vaccine.
-
ICON to partner with US government agency to test COVID vaccine candidates
This news article from Reuters outlines that, as part of the collaboration with Biomedical Advanced Research and Development Authority, ICON will conduct a mid-stage trial of 10,000 participants to assess the efficacy of a next generation COVID-19 vaccine relative to currently available shots.
-
ICON to conduct U.S. government trial of next-gen COVID-19 vaccines
This news article, published on FIERCE Biotech, highlights that ICON is partnering with the U.S. Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA) to conduct a clinical trial to evaluate next-generation vaccines for COVID-19.
-
Disease surveillance and vaccine development
In this article in Life Science Review, Dinah Knotts, Vice President, project management, Vaccines and Infectious Disease, ICON plc outlines how disease surveillance can play an important role in emerging infectious disease early.
-
Developing mRNA vaccine technology
In this article, Dinah Knotts, Vice President of Project Management at ICON, speaks about mRNA vaccine technology and what further opportunities it can offer in fighting infectious diseases.
-
The contribution of companies during the Covid-19 pandemic
Rose Kidd, President, Operations Delivery outlines the role ICON played in the search for vaccines and treatments for Covid-19 in the American Chamber of Commerce Ireland 2023 US-Ireland Business Report.
2023 American Chamber of Commerce Ireland
-
Life sciences industry an active player in pandemic response
Rose Kidd outlines the role ICON played in the global response to the COVID-19 pandemic in the Irish Times Life Sciences special report.
2022 The Irish Times DAC
-
Measuring the cost-effectiveness of vaccines targeting infectious diseases
ICON's Richard Pitman and Pragya Khurana provide insights on the use of real world evidence to build cost-effectiveness models that demonstrate the value that vaccines bring to healthcare systems.
